本帖最后由 老马 于 2012-1-13 21:20 编辑
! D- Q! b) ?1 k" O' P+ @: g8 V
0 ~8 n, V8 \/ j* i爱必妥和阿瓦斯丁的比较
. J9 W# {" J) m% w
1 {; g4 O! X: }2 \, H
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 Y( y0 J. J; e
$ y6 o6 Y6 ?; A, Z
( e" \( Z7 X; }http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" p8 b8 ]4 ?$ ^4 P1 K==================================================5 H1 O& u! A- ]5 W, I
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 c: v0 v/ x$ a4 K! h" f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 b' E6 M& k) a. |) P) k4 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) H0 U3 C- n/ I2 c+ r5 a
|